Medicinal chemistry

Domain Therapeutics Promotes Stephan Schann as Chief Scientific Officer (CSO)

Retrieved on: 
Tuesday, February 27, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, PAR2, Multimedia, G protein-coupled receptor, Growth, Medicinal chemistry, Evotec, University, Therapy, GPCR, Gq alpha subunit, Biomedical Research, Patient, Intellectual property, Knowledge, CSO, Cancer

Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the expansion of the Company’s executive management team with the appointment of Stephan Schann as Chief Scientific Officer (CSO).

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the expansion of the Company’s executive management team with the appointment of Stephan Schann as Chief Scientific Officer (CSO).
  • Stephan will oversee the development of Domain’s proprietary pipeline and its highly innovative R&D center based in Strasbourg, France.
  • Stephan has also contributed significantly to the Company’s scientific achievements and strategic direction.
  • Dr. Tony Johnson, President and Chief Executive Officer of Domain Therapeutics, said: “We are thrilled to have Stephan be promoted into the role of Chief Scientific Officer.

Atomic AI Announces Appointments of New Independent Member to its Board of Directors and Additions to the Scientific Advisory Board

Retrieved on: 
Thursday, February 22, 2024
Research, Other Health, General Health, Pharmaceutical, Infectious Diseases, Hospitals, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, Other Science, Molecule, Organic chemistry, Viral, Senior, Janssen Pharmaceuticals, Dartmouth College, SAB, Neuroscience, Beclabuvir, PTC Therapeutics, University, RNA, Jan Vansina, RSV, HIV-1, Atomic, Johnson & Johnson, Stroke, Bristol Myers Squibb, MBA, BMS, Therapy, Journal, HCV, PTC, Drug discovery, Meanwell, McArdle Laboratory, American Academy, Royal Society, Daclatasvir, Harvard University, Asunaprevir, Doctor of Philosophy, Thrombosis, Rutgers University, Patient, Outline of physical science, American Chemical Society, Deep learning, Publication, Cancer, Medicinal chemistry, Pharmaceutical industry

Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the appointment of Stuart Peltz, Ph.D. as an independent board member to the Atomic AI Board of Directors, and the additions of Percy Carter, MBA, Ph.D., and Nicholas Meanwell, Ph.D. to their Scientific Advisory Board (SAB).

Key Points: 
  • Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the appointment of Stuart Peltz, Ph.D. as an independent board member to the Atomic AI Board of Directors, and the additions of Percy Carter, MBA, Ph.D., and Nicholas Meanwell, Ph.D. to their Scientific Advisory Board (SAB).
  • “We are extremely pleased to have these highly regarded, experienced biotech leaders join in our efforts and believe in our mission,” said Raphael Townshend, Ph.D., Founder and CEO of Atomic AI.
  • Peltz’s experience will help shape our strategy as we endeavor to streamline the discovery and development of novel therapies.
  • “They have demonstrated tremendous progress integrating deep learning foundation models with experimental results to be able to predict and optimize RNA structures to enable rational drug design.

OcuSciences Welcomes Michael Patane, PhD, to its Board of Directors

Retrieved on: 
Tuesday, February 20, 2024
Medical Devices, Health, Diabetes, Pharmaceutical, Optical, Biotechnology, Therapy, Acquisition, Doctor of Philosophy, Drug discovery, Mitochondrion, History, Biomedical Research, DSM-IV codes, Knowledge, Takeda Oncology, Medicinal chemistry, Pharmaceutical industry

OcuSciences, a medical device company developing ocular imagers to detect early disease by assessing retinal metabolic activity, today announced the addition of Michael Patane, PhD, to its Board of Directors.

Key Points: 
  • OcuSciences, a medical device company developing ocular imagers to detect early disease by assessing retinal metabolic activity, today announced the addition of Michael Patane, PhD, to its Board of Directors.
  • "We are thrilled to welcome Dr. Michael Patane to our Board of Directors," said Kurt Riegger, CEO at OcuSciences.
  • “OcuSciences is at a very exciting time in its history as it builds momentum around its novel and patented retinal disease detection modality,” said Dr. Michael Patane.
  • “I am honored to join this Board and look forward to working with my fellow directors and senior management to help OcuSciences advance the development and commercialization of its transformative retinal imaging devices.”

Immunic to Participate in Investor and Scientific Conferences in March

Retrieved on: 
Thursday, March 7, 2024
Virology, Biotechnology, Conference, Society, Doctor of Philosophy, Abstract, Poster, Communication, Medicinal chemistry, Pharmaceutical industry

Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, and Jessica Breu, Vice President Investor Relations and Communications, will participate in one-on-one investor meetings at this conference in Miami, FL.

Key Points: 
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, and Jessica Breu, Vice President Investor Relations and Communications, will participate in one-on-one investor meetings at this conference in Miami, FL.
  • Two abstracts have been accepted for poster presentations at this conference in Munich, Germany.
  • The poster presentations will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Two abstracts have been accepted for poster and oral presentations at this conference in Vienna, Austria.

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, February 15, 2024
Fast Track, BTK, MCL, Research, B-cell lymphoma, ASH, NHL, Inflammation, FDA, CLL, Calendar, Mantle cell lymphoma, Manuscript, Medicinal chemistry, Lymphocytosis, BCL2, Lymphoma, Society, Chronic lymphocytic leukemia, Therapy, Pharmacology, Accelerated approval (FDA), Rheumatoid arthritis, Lymphoid leukemia, Paclitaxel, Non-Hodgkin lymphoma, Patient, Journal, Clinical trial, Science, IND, Publication, Trial of the century, DLBCL, Cancer, Priority review, Pharmaceutical industry

NX-2127 exhibited dose-dependent PK, leading to robust and sustained degradation of BTK and biologically relevant degradation of IKZF1 (Ikaros).

Key Points: 
  • NX-2127 exhibited dose-dependent PK, leading to robust and sustained degradation of BTK and biologically relevant degradation of IKZF1 (Ikaros).
  • NX-2127 had a manageable safety profile that was consistent with previous reports for BTK-targeted and immunomodulatory therapies.
  • During the year ended November 30, 2023, Nurix achieved research milestones under its collaborations with Gilead and Sanofi totaling $12.5 million and $7.0 million, respectively.
  • Cash, cash equivalents and marketable securities was $295.3 million as of November 30, 2023, compared to $268.7 million as of August 31, 2023.

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Retrieved on: 
Wednesday, February 7, 2024
ARD International Music Competition, Growth, Wesleyan University, Biophysical chemistry, Chairperson, Harvard University, DLB, Caregiver, Medicinal chemistry, Patient, Laboratory, CRVO, Vertex Pharmaceuticals, Philosophy, Inflammation, Drug design, Doctorate, Brain, Immunology, Drug development, Merck, Lewy body, Merck & Co., Dementia, Master, Pharmaceutical industry

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board. Dr. Boger is an innovative scientist and highly successful business executive who brings extensive drug development and biopharmaceutical company leadership experience to CervoMed as it progresses toward an important inflection point. Topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod in dementia with Lewy bodies (DLB) is expected in the second half of 2024. The Board Chair position was formerly held by CervoMed co-founder Dr. Sylvie Gregoire, who will continue to serve as a director.

Key Points: 
  • The Board Chair position was formerly held by CervoMed co-founder Dr. Sylvie Gregoire, who will continue to serve as a director.
  • “It is a pleasure to welcome Joshua, the founder of Vertex and an esteemed industry leader, to our Board of Directors,” said John Alam, M.D., Chief Executive Officer of CervoMed.
  • Dr. Joshua Boger is an industry veteran who has served in multiple scientific and business leadership roles in his 40+ year career.
  • He continued to serve on the Vertex Board and Chair Vertex’s Science & Technology Committee until 2017.

Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader

Retrieved on: 
Thursday, February 1, 2024
Manuscript, BTK, Lymphoid leukemia, Pharmacokinetics, SAN, Growth, Mantle cell lymphoma, City, Research, MCL, CLL, Medicinal chemistry, Patient, Safety, Pharmacology, Publication, Inflammation, Blood, BCR, Therapy, Journal, DLBCL, University, Chronic lymphocytic leukemia, Cancer

SAN FRANCISCO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the publication of a manuscript in the journal Science titled: “Kinase Impaired BTK Mutations Are Susceptible to Clinical Stage BTK and IKZF1/3 Degrader NX-2127” that elucidates a previously unappreciated oncogenic scaffold function of BTK responsible for clinical resistance to enzymatic inhibitors and shows that NX-2127, a potent targeted protein degrader with differentiated activity against BTK and IKZF1/3, can overcome this resistance across a broad range of acquired mutations.

Key Points: 
  • “While BTK inhibitors have positively changed clinical outcomes for patients with B-cell malignancies, the emergence of acquired resistance to these medicines is a growing clinical problem,” said Alexey Danilov, M.D., Ph.D.
  • Professor and Co-Director, Toni Stephenson Lymphoma Center, City of Hope National Medical Center.
  • “With the ability to target BTK inhibitor resistance mutations and achieve clinical responses, we believe that BTK degraders have the potential to become the next dominant class of agents in the significant BTK-targeted therapy field.
  • We look forward to presenting additional clinical data from this program, and from our NX-5948 BTK degrader program, which is also being evaluated in patients with CLL, at future medical meetings.”

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Retrieved on: 
Thursday, February 1, 2024
Growth, Novartis, Drug, AMD, Food and Drug Administration, Ophthalmology, Medicinal chemistry, Patient, Wake Forest University, FDA, Doctor of Pharmacy, Geographic atrophy, SVP, Retina, Food, Drug development, Doctor of Philosophy, ASX, Retinal, China Pharmaceutical University, U.S. FDA

MELBOURNE, Australia, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development, and Fang Li, Ph.D. RAC, as SVP, Regulatory Affairs, effective February 1, 2024. Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer, Frederic Guerard, PharmD, MS, and will join the Opthea Executive Management Team.

Key Points: 
  • Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer, Frederic Guerard, PharmD, MS, and will join the Opthea Executive Management Team.
  • The majority of my career has been dedicated to the clinical development of novel therapies for retinal diseases.
  • She has held key roles at prominent ophthalmology companies such as Novartis AG, Alcon Inc., and Bausch + Lomb Corporation.
  • Dr. Li's extensive background includes significant involvement in health authority interactions, U.S. FDA advisory committee meeting preparation and the establishment and leadership of regulatory teams.

Synnovation Therapeutics Launches with $102 Million to Advance Clinical-Stage Pipeline of Precision Therapies Targeting Highly Validated Disease Pathways

Retrieved on: 
Wednesday, January 24, 2024
Pharmaceutical, Health, Oncology, Other Health, Entrepreneurship, Vitiligo, Patient, Incyte, Therapy, Rheumatoid arthritis, JAK, Third Rock Ventures, Molecular biology, Pharmacology, Cancer, Medicine, Drug discovery, FGFR, Cholangiocarcinoma, Ruxolitinib, Non-small-cell lung cancer, COVID-19, Atopic dermatitis, PARP1, FDA, Polycythemia, Eli Lilly and Company, Medicinal chemistry, Drug, EVP, GPH, CNS, Pharmaceutical industry

Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.

Key Points: 
  • Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.
  • Synnovation was founded by a world-class medicinal chemistry team with a track record of developing best-in-class therapeutics.
  • Proceeds will fund the advancement of the company’s clinical and preclinical pipeline, including SNV1521 and SNV4818, as well as additional programs.
  • The company’s lead program, SNV1521, is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor.

Plexium Announces Appointment of Michael Martin, Ph.D. as President and CEO

Retrieved on: 
Tuesday, January 16, 2024
SMARCA2, Research, Biology, Analytical chemistry, Sanofi, TPD, SAN, University, Business development, Cancer, Evaluation, Takeda Pharmaceutical Company, Medicinal chemistry, CDK2, Pharmaceutical industry

SAN DIEGO, Jan. 16, 2024 /PRNewswire/ -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Michael Martin, Ph.D. as President and Chief Executive Officer, and a member of the Board of Directors.

Key Points: 
  • SAN DIEGO, Jan. 16, 2024 /PRNewswire/ -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Michael Martin, Ph.D. as President and Chief Executive Officer, and a member of the Board of Directors.
  • "I look forward to working with Mike to advance our clinical-stage pipeline and progressing more TPD programs against important cancer targets into the clinic."
  • I am excited to lead Plexium and continue to build a leading TPD company focused on improving patients' lives."
  • Dr. Martin joined Takeda in 2012 and prior to his most recent role, he was President of Takeda Ventures, Inc., Takeda's corporate venture capital company.